โ† All deals

Regencell Bioscience Holdings Ltd

Public Equity (Nasdaq)BiotechnologyTraditional Chinese MedicinePublic Company
๐Ÿ“ Causeway Bay, Hong Kongโ€ข Founded 2014
StreetZero Signal 56
Be the first to signal interest

About Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It targets treatments for neurocognitive disorders and degenerative diseases. The company is publicly traded on NASDAQ under ticker RGC following its 2021 IPO. It reports zero revenue and ongoing operating losses.

LATEST FUNDINGRule 144
$170K
Announced 2026-11-17
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Regencell Bioscience Holdings Ltd.

Free plan includes 3 full deal profiles every month.

Investors

Not disclosed in the source filing. Form D filings do not list investors โ€” StreetZero surfaces them from news where available.

Key highlights

  • Publicly traded on NASDAQ:RGC since July 2021 IPO
  • Develops TCM therapies for neurocognitive and degenerative conditions
  • Reports zero annual revenue and negative EBITDA of approximately -11.6M USD
  • Headquartered in Hong Kong with market cap near 94M USD as of late 2024

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account